Trending...
- Phillip A. Villanueva, MD, ABNS, is being recognized by Continental Who's Who
- Beyond Visionary Has Partnered With Heal America To Host INFORM Dallas
- World's First Walkie-Talkie Bone Conduction Sport Headphones
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith reminds investors of the upcoming June 27, 2022 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Natera, Inc. ("Natera" or the "Company") (NASDAQ: NTRA) common stock between February 26, 2020 and April 19, 2022, inclusive (the "Class Period").
Investors suffering losses on their Natera investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in this class action at 888-638-4847 or by email to howardsmith@howardsmithlaw.com.
On January 1, 2022, an article from the New York Times called into question the accuracy of certain prenatal tests, including Natera's Panorama test, alleging that positive results on tests are incorrect approximately 85 percent of the time, and that patients who receive a positive result are supposed to pursue follow-up testing, which "can cost thousands of dollars, come with a small risk of miscarriage and can't be performed until later in pregnancy."
On this news, Natera's stock price fell $5.35, or 5.7%, over two trading days to close at $88.04 per share on January 4, 2022, thereby injuring investors.
Then, on January 14, 2022, a nonprofit watchdog group filed a complaint with the SEC requesting an investigation into whether Natera had "repeatedly" claimed that its tests were "much more reliable than it appears they really are."
More on The PennZone
On this news, Natera's stock fell $6.29, or 9.3%, to close at $61.08 per share on January 18, 2022.
On March 9, 2022, Hindenburg Research published a report which alleged, among other things, that Natera's revenue growth has been "fueled by deceptive sales and billing practices aimed at doctors, insurance companies and expectant mothers."
On this news, Natera's stock price fell $17.95, or 32.8%, to close at $36.80 per share on March 9, 2022, thereby further injuring investors.
Then, on March 14, 2022, a Delaware District Court jury found that Natera had engaged in false advertising, including claims that its kidney transplant test, Prospera, was more accurate than its competing tests.
On this news, Natera's stock price fell $5.57 per share, or 15.5%, to close at $30.32 per share on March 15, 2022, thereby further injuring investors.
Then, on April 19, 2022, the United States Food and Drug Administration ("FDA") issued a safety communication "to educate patients an health care providers and to help reduce the inappropriate use" of non-invasive prenatal tests ("NIPT"), cautioning that NIPTs reliability and accuracy "may not be supported with sound scientific evidence," revealing that there had been "cases where a screening test reported a genetic abnormality and a confirmatory diagnostic test later found that the fetus was healthy."
On this news, Natera's stock fell $1.53, or 3.9%, to close at $38.63 per share on April 19, 2022, thereby injuring investors further.
The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) Panorama was not reliable and resulted in high rates of false positives; (2) Prospera did not have superior precision compared to competing tests; (3) as a result of Defendants' false and misleading claims about Natera's technology, the Company was exposed to substantial legal and regulatory risks; (4) Natera relied upon deceptive sales and billing practices to drive its revenue growth; and (5) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.
More on The PennZone
If you purchased or otherwise acquired Natera common stock during the Class Period, you may move the Court no later than June 27, 2022 to ask the Court to appoint you as lead plaintiff if you meet certain legal requirements. To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020, by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to howardsmith@howardsmithlaw.com, or visit our website at www.howardsmithlaw.com.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Contacts
Law Offices of Howard G. Smith
Howard G. Smith, Esquire
215-638-4847
888-638-4847
howardsmith@howardsmithlaw.com
www.howardsmithlaw.com
Investors suffering losses on their Natera investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in this class action at 888-638-4847 or by email to howardsmith@howardsmithlaw.com.
On January 1, 2022, an article from the New York Times called into question the accuracy of certain prenatal tests, including Natera's Panorama test, alleging that positive results on tests are incorrect approximately 85 percent of the time, and that patients who receive a positive result are supposed to pursue follow-up testing, which "can cost thousands of dollars, come with a small risk of miscarriage and can't be performed until later in pregnancy."
On this news, Natera's stock price fell $5.35, or 5.7%, over two trading days to close at $88.04 per share on January 4, 2022, thereby injuring investors.
Then, on January 14, 2022, a nonprofit watchdog group filed a complaint with the SEC requesting an investigation into whether Natera had "repeatedly" claimed that its tests were "much more reliable than it appears they really are."
More on The PennZone
- Distinguished New York Trial Attorney and Author Donates Book Proceeds to NYU Cancer Research Center
- Treat Yourself Right This Summer With LA's Best Massage Therapy for Serious Pain Relief Near You!
- Governor Wolf: Pennsylvania's New, Lower Corporate Tax Rate Will Attract Businesses, Good Jobs
- Leading Hospitality Advisor Joins Whiteford in Pittsburgh
- Gospel Charting Artist Jeremiah Nedu Is On The Rise With New Single "Your Mercy"
On this news, Natera's stock fell $6.29, or 9.3%, to close at $61.08 per share on January 18, 2022.
On March 9, 2022, Hindenburg Research published a report which alleged, among other things, that Natera's revenue growth has been "fueled by deceptive sales and billing practices aimed at doctors, insurance companies and expectant mothers."
On this news, Natera's stock price fell $17.95, or 32.8%, to close at $36.80 per share on March 9, 2022, thereby further injuring investors.
Then, on March 14, 2022, a Delaware District Court jury found that Natera had engaged in false advertising, including claims that its kidney transplant test, Prospera, was more accurate than its competing tests.
On this news, Natera's stock price fell $5.57 per share, or 15.5%, to close at $30.32 per share on March 15, 2022, thereby further injuring investors.
Then, on April 19, 2022, the United States Food and Drug Administration ("FDA") issued a safety communication "to educate patients an health care providers and to help reduce the inappropriate use" of non-invasive prenatal tests ("NIPT"), cautioning that NIPTs reliability and accuracy "may not be supported with sound scientific evidence," revealing that there had been "cases where a screening test reported a genetic abnormality and a confirmatory diagnostic test later found that the fetus was healthy."
On this news, Natera's stock fell $1.53, or 3.9%, to close at $38.63 per share on April 19, 2022, thereby injuring investors further.
The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) Panorama was not reliable and resulted in high rates of false positives; (2) Prospera did not have superior precision compared to competing tests; (3) as a result of Defendants' false and misleading claims about Natera's technology, the Company was exposed to substantial legal and regulatory risks; (4) Natera relied upon deceptive sales and billing practices to drive its revenue growth; and (5) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.
More on The PennZone
- Essential Utilities Appoints New Chief of Staff
- Peer-Reviewed Study Shows Measurable Impact on Employee Health and Productivity from Employee Assistance Program
- HWS Announces Top 10 Low Cost Vacation Spots
- World's First Walkie-Talkie Bone Conduction Sport Headphones
- INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Fulgent Genetics, Inc. (FLGT) on Behalf of Investors
If you purchased or otherwise acquired Natera common stock during the Class Period, you may move the Court no later than June 27, 2022 to ask the Court to appoint you as lead plaintiff if you meet certain legal requirements. To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020, by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to howardsmith@howardsmithlaw.com, or visit our website at www.howardsmithlaw.com.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Contacts
Law Offices of Howard G. Smith
Howard G. Smith, Esquire
215-638-4847
888-638-4847
howardsmith@howardsmithlaw.com
www.howardsmithlaw.com
Filed Under: Business
0 Comments
Latest on The PennZone
- Gov. Wolf: Education Funding Is an Investment in Pennsylvania's Future
- Pennsylvania: Wolf Administration: Hunger-Free Campus Initiative Helps College Students Access Free Nutritious Food Options
- 3i Solutions Announces New Leadership Brings a Customer-Focused Approach
- CHOP Helps Develop Platform to Speed Up Drug Development for Kids with Cancer
- Rite Aid Opens Online Scheduling for Flu Vaccines at All Locations
- Ecovyst Announces Upsize and Pricing of Secondary Offering of 13,000,000 Shares of Common Stock by Selling Stockholders and Repurchase of Common Stock
- CORRECTING and REPLACING Aurora Announces Second Quarter 2022 Results
- Help Wanted: Oakland-Based Children Rising Seeks Volunteers to Help Students Overcome COVID-Related Learning Loss
- E3 Forensic Platform Innovates again with Remote Cloud Collection
- INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Carvana Co. (CVNA) Investors
- Governor Wolf Announces More Than $8 Million in Funding to Support Business Growth, Job Creation in Six Pennsylvania Counties
- Zonit Launches the World's Best Automatic Transfer Switch for Industrial & Commercial Applications
- Bridget Rose Productions is producing the short documentary - "FORCE" RECON
- U. S. Steel Foundation Awards College Scholarships to Employees' Children
- Children's Hospital of Philadelphia Appoints New Chief of Critical Care Medicine
- Pennsylvania: Governor Wolf Announces $190 Million Available for Schools to Promote Healthier, Safer Environments
- Aramark Declares Quarterly Dividend
- Institutional Property Advisors Brokers $85.7 Million Grocery-Anchored Power Center Sale
- Sea Island Writers Retreat and chromatic black™ Host Three Virtual Writing Workshops
- US Dollar Provides Exceptional Value For Sightseeing Trips To Italy, Havana, Cuba, Delhi, Agra and Jaipur and Barcelona, Spain